Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews

Like the Progress Educational Trust on Facebook


 


 

Review supports existence of the 'placebome'

20 April 2015

By Ruth Retassie

Appeared in BioNews 798

Some people may be genetically more likely to experience the 'placebo effect', according to a review of recent studies.

The paper, published in Trends in Molecular Biology, finds that research over the last decade implicates genetics in the placebo effect, primarily through influences on neurotransmitters and the way the brain responds to pain and reward.

'Genetic sequencing is revealing that the placebo response is, in fact, a complex phenotype with an unfolding physiology,' said lead author Dr Kathryn Hall from Program in Placebo Studies (PiPS) at Beth Israel Deaconess Medical Center and Harvard Medical School, USA.

'The study of genomic effects on the placebo response - what we call "the placebome" - is in its infancy, but there is already ample evidence that genetic variations in the brain's neurotransmitter pathways modify placebo effects.'

The first evidence for this came in 2012, when Dr Hall and her team published research in PLoS One exploring the genetics of catechol-O-methyltransferase (COMT), an enzyme that controls dopamine production in the brain and is connected to pain and pleasure.

Patients with irritable bowel syndrome were either put on a waiting list for treatment, given fake acupuncture by an unfriendly provider or fake acupuncture by a warm and caring provider.

The researchers then tested patients to see which version of the COMT gene they had. Patients with a high-dopamine variant of the gene were more likely to report that placebo treatment had improved their symptoms than patients with a low-dopamine variant of the gene - a response that was even greater when they were treated by a caring practitioner.

However, based on their current review, the team say that COMT is likely to represent just one gene and one neurotransmitter pathway involved in the placebo effect. They say that their round-up of the evidence supports the existence of a so-called 'placebome' - a network of genes involved in determining an individual's response to placebo.

'Our findings strongly support the idea that genetic signatures for placebo responses exist, but our findings are preliminary,' Dr Hall told Reuters. 'Something is definitely there, but more needs to be known.'

The team say that as knowledge of placebos increases, it may allow for those who respond to placebos to require smaller doses of treatment. This personalised approach to drug dosages could improve the experience of treatment for many patients, and they may experience fewer side effects.

The researchers also speculate that the findings could mean that the design of clinical trials will have to be changed in future to include a group that receives no treatment in addition to a group that receives a placebo, in order to gauge the magnitude of the placebo effect.

'As we think about personalised medicine… I think it's important that we don't forget the element that comes from the placebo response,' Dr Hall told Reuters. 'In a way, it's the most well studied treatment that has never been studied.'

SOURCES & REFERENCES
PBS Newshour | 15 April 2015
 
Trends in Molecular Medicine | 13 April 2015
 
Reuters | 16 April 2015
 
The Atlantic | 13 April 2015
 
Beth Israel Deaconess Medical Center | 13 April 2015
 

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

02 September 2013 - by Dr Victoria Burchell 
A variant of a gene involved in energy storage in muscles may be linked to problems experienced by some users of the cholesterol-lowering drugs statins...
17 September 2012 - by James Brooks 
Genetic tests that could greatly improve the effectiveness of drug therapy for a wide variety of conditions are being underused or ignored, a leading expert says...
23 May 2011 - by Nishat Hyder 
'Will pharmacogenetics lead to colour-coded medicine?' was the question posed at the Progress Educational Trust (PET)'s panel discussion on 10 May 2011. This event, which is part of a wider project, 'Genes, ancestry and racial identity: Does it matter where your genes come from?' was held at the Foresight Centre, University of Liverpool...
23 February 2009 - by Antony Blackburn-Starza 
A new method of calculating the correct amount of warfarin - an anti-blood clotting medicine given to patients at risk of heart attacks or strokes - is believed to be more accurate that the current practice of adjusting the standard dosage through trial and error. The right amount of...
08 December 2008 - by Dr Charlotte Maden 
The susceptibility of patients to the placebo effect has been linked to a gene by researchers in Sweden. The findings, published in the Journal of Neuroscience, provide clues as to how some patients can respond to taking a placebo, usually a sugar pill, instead of the real...

HAVE YOUR SAY
Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions


- click here to enquire about using this story.

Published by the Progress Educational Trust

CROSSING FRONTIERS

Public Conference
London
8 December 2017

Speakers include

Professor Azim Surani

Professor Magdalena Zernicka-Goetz

Professor Robin Lovell-Badge

Sally Cheshire

Professor Guido Pennings

Katherine Littler

Professor Allan Pacey

Dr Sue Avery

Professor Richard Anderson

Dr Elizabeth Garner

Dr Andy Greenfield

Dr Anna Smajdor

Dr Henry Malter

Vivienne Parry

Dr Helen O'Neill

Dr César Palacios-González

Philippa Taylor

Fiona Fox

Sarah Norcross

Sandy Starr


BOOK HERE

Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation